Don’t forget about the effect it could have with a hostile takeover.
If he could get an ultra rare and/or Rett to market before the bigger trial readout, one would think investors/tutes would open their eyes and understand the possibilities.
There is also, for the orphan rare diseases with poor SOC, a marketable voucher. Company is doing a great job of expediting pipeline development, esp during a pandemic.
Market Data 
Markets 
AI
